Study Testing Response Effect of KY1005 Against Moderate to Severe Atopic Dermatitis The STREAM-AD Study
Status:
Not yet recruiting
Trial end date:
2024-05-20
Target enrollment:
Participant gender:
Summary
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind,
5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult
participants with moderate to severe atopic dermatitis.
The estimated duration is 4±1 weeks of screening and run-in period, followed by a 365 days
double blinded treatment period with additional 84 days safety follow-up up to Day 449.